Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: Results of a study in a primary care setting

World Journal of Gastroenterology

Volumn 12, Issue 16, 2006, Pages 2569-2573

  des Varannes, Stanislas Bruley ^a   Sacher Huvelin, Sylvie ^a   Vavasseur, Fabienne ^a   Masliah, Claude ^a   Le Rhun, Marc ^a   Aygalenq, Philippe ^c   Bonnot Marlier, Sylvie ^d   Lequeux, Yves ^b   Galmiche, Jean Paul ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b CH Draguignan ^*  (France)

^c CH de Draguignan   (France)

^d Laboratoires Janssen CILAG   (France)

Author keywords

Diagnostic tool; Gastro oesophageal reflux disease; Primary care; Proton pump inhibitors

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIARRHEA; DISCRIMINANT ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DYSLIPIDEMIA; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; GENERAL PRACTITIONER; HUMAN; INSOMNIA; LYMPHADENITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIMARY MEDICAL CARE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY; URINARY TRACT INFECTION; VOMITING;

EID: 33646461863     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i16.2569     Document Type: Article

References (19)

1. Bruley des Varannes S. The proton-pump inhibitor test: pros and cons. Eur J Gastroenterol Hepatol 2004; 16: 847-852
2. Sachs G, Humphries TJ. Rabeprazole: pharmacology, pharmacokinetics, and potential for drug interactions. Introduction. Aliment Pharmacol Ther 1999; 13 Suppl 3:1-2
3. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17:1507-1514
4. Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors - focus on rabeprazole. Aliment Pharmacol Ther 2004; 20 Suppl 6:11-19
5. Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 2002; 16:1811-1817
6. Pehl C, Boccali I, Hennig M, Schepp W. pH probe positioning for 24-hour pH-metry by manometry or pH step-up. Eur J Gastroenterol Hepatol 2004; 16: 375-382
7. Wiener GJ, Richter JE, Copper JB, Wu WC, Castell DO. The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol 1988; 83: 358-361
8. Shi G, Bruley des Varannes S, Scarpignato C, Le Rhun M, Galmiche JP. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 1995; 37: 457-464
9. Weusten BL, Akkermans LM, vanBerge-Henegouwen GP, Smout AJ. Symptom perception in gastroesophageal reflux disease is dependent on spatiotemporal reflux characteristics. Gastroenterology 1995; 108: 1739-1744
10. Johnsson F, Hatlebakk JG, Klintenberg AC, Roman J, Toth E, Stubberod A, Falk A, Edin R. One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease. Scand J Gastroenterol 2003; 38: 354-359
11. Fass R. Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis 2000; 18: 20-26
12. Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002; 16:1301-1307
13. Bruley des Varannes S, Gharib H, Bicheler V, Delchier JC, Stanescu L, Bonaz B, Bost R, Bonnot-Marlier S. Low doses of rabeprazole and omeprazole: Effects on gastric acidity. Results of a double blind, randomized and placebo-controlled study in healthy subjects. Aliment Pharmacol Ther 2004; 20: 899-907
14. Oda K, Iwakiri R, Hara M, Watanabe K, Danjo A, Shimoda R, Kikkawa A, Ootani A, Sakata H, Tsunada S, Fujimoto K. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. Dig Dis Sci 2005; 50: 1921-1926
15. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004,140:518-527
16. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Festen HP, Jansen EH, Tuynman HA, Schrijver M, Dieleman LA, Meuwissen SG. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92: 1997-2000
17. Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastrooesophageal reflux disease. Seand J Gastroenterol 1998; 33: 15-20
18. Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002; 97: 1332-1339
19. French-Belgian Consensus Conference on Adult Gastro-oesophageal Reflux Disease 'Diagnosis and Treatment': report of a meeting held in Paris, France, on 21-22 January 1999. The Jury of the consensus conference. Eur J Gastroenterol Hepatol 2000; 12:129-137